Akero Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKRO and other ETFs, options, and stocks.About AKRO
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
CEOAndrew Cheng
CEOAndrew Cheng
Employees56
Employees56
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2017
Founded2017
Employees56
Employees56
AKRO Key Statistics
Market cap1.74B
Market cap1.74B
Price-Earnings ratio-8.57
Price-Earnings ratio-8.57
Dividend yield—
Dividend yield—
Average volume1.77M
Average volume1.77M
High today$25.43
High today$25.43
Low today$23.74
Low today$23.74
Open price$24.62
Open price$24.62
Volume834.10K
Volume834.10K
52 Week high$58.38
52 Week high$58.38
52 Week low$11.25
52 Week low$11.25
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%